FDA OKs Secukinumab Label Update for Psoriatic Arthritis

Article

The label update includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.

Officials with the FDA have approved a label update for secukinumab (Cosentyx, Novartis) that includes new evidence that the treatment significantly impedes the progression of joint structural damage at 24 weeks compared to placebo for patients with active psoriatic arthritis.

"While daily psoriatic arthritis symptoms can seriously affect a patient, the progressive nature of this disease should not be ignored. The joint damage that often results from having the disease over time can potentially be permanent," said Marcia Kayath, MD, PhD, MBA, Head US Clinical Development and Medical Affairs, Novartis.

Secukinumab is a human monoclonal antibody that selectively binds to the interleukin-17A cytokine, impeding its interaction with the IL-17 receptor. The drug is now the only interleukin-17A antagonist approved to treat active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe plaque psoriasis in adults.

Click to continue reading on MD Magazine.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
Image credit: gamjai - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.